Laboratory/pathology
News • Research support
Stem cell therapy for traumatic injury on the horizon
University of Texas Health receives funding for study
Adult sensory neurons (purple) are protected from attack by activated macrophages (blue) when cultured with MultiStem (green).
Source: Athersys, Inc.
The University of Texas Health Science Center at Houston (UTHealth) has received funding through a public/private partnership for the first-ever clinical trial investigating a stem cell therapy for early treatment and prevention of complications after severe traumatic injury. The proposed Phase 2 trial is underwritten with $2 million from the Medical Technology Consortium (MTEC) and $1.5 million from Memorial Hermann Foundation. Athersys, Inc., will provide MultiStem, the investigational clinical product for the trial, and provide regulatory and operational support, as its contribution to the trial.
"Traumatic injury is the leading cause of death and disability among children and members of the military, and also has a significant impact on the elderly. Following serious trauma, an acute hyperinflammatory response can be triggered, impairing recovery and leading to additional complications," said Charles S. Cox, Jr., M.D., principal investigator, George and Cynthia Mitchell Distinguished Chair in Neurosciences at McGovern Medical School at UTHealth and co-director of the Red Duke Trauma Institute at Memorial Hermann-Texas Medical Center. "Our prior research demonstrates that administration of MultiStem following acute neurological injury can help improve recovery and reduce the occurrence or severity of certain complications, so we are excited about the clinical potential in this area."
Following serious trauma, an acute hyperinflammatory response can be triggered, impairing recovery and leading to additional complications
Charles S. Cox
Cox and other researchers at McGovern Medical School at UTHealth have been studying MultiStem in preclinical and clinical trials as a possible therapy for traumatic brain injury and stroke for the past 10 years.
According to the Centers for Disease Control, traumatic injury is the third-leading cause of death in the US and the leading cause in Americans ages 1 to 44. Most deaths occur in the first three days from uncontrolled bleeding and traumatic brain injury, but 25 percent of deaths occur after three days from factors such as inflammatory-related complications. Those secondary complications can include acute kidney injury, acute respiratory distress syndrome, venous thromboembolic disease and swelling and tissue death after traumatic brain injury.
The proposed randomized, double-blind, placebo-controlled Phase 2 clinical trial must still go through review by the US Food and Drug Administration and approval from the UTHealth Internal Review Board, and therefore, the design is subject to additional input. Researchers hope to enroll approximately 150 severely injured trauma patients within hours of hospitalization at Memorial Hermann-TMC, the busiest Level 1 trauma center in the country.
Source: University of Texas Health Science Center at Houston
More on the subject:
stem cells (125)
studies (569)
therapy (754)
traumatology (73)
I'm interested in more information …
Read all latest stories
News • Making tumours susceptible to chemo
Breast cancer: target protein may hold key to therapy success
A rare variant of a protein present in nearly all human cells may hold the key to improving the effectiveness of breast cancer treatment, according to University of Manchester research.
#breast cancer
#chemotherapy
#stem cells
#tumour
News • After blood stem cell transplantation
How the immune system "reboots" in MS patients
Blood stem cell transplantation is a radical but highly effective therapy for multiple sclerosis. A study examined how the treatment curbs the disease and how the immune system regenerates afterwards.
#immune system
#studies
News • CRISPR
Could gold be the key to making gene therapy for HIV?
A proof-of-principle study shows that gold nanoparticles loaded with CRISPR and other gene-editing tools safely and effectively edited blood stem cells.
#HIV/AIDS
#infections
Multi-Modality Suites
Canon · Alphenix 4D CT
Canon Medical Systems Europe B.V.
Promega – Maxwell CSC 48 Instrument
Promega GmbH
Research Use Only
Sarstedt – Low DNA Binding Micro Tubes
SARSTEDT AG & CO. KG
Shimadzu – CLAM-2030 CL (IVD)/ CLAM-2030 (RUO)
Shimadzu Europa GmbH
Shimadzu – LCMS-8060NX CL (IVD) / LCMS-8060 NX (RUO)
Shimadzu – MALDImini-1
Manufacturer-Index
To Homepage?
I am interested in ... ------------------------- All topics Surgery Health IT Oncology Research Cardiology Neurology Laboratory Pathology Radiology Ultrasound
This website uses cookies to give our readers the best website experience.
Please refer to our privacy policy to find out how we use cookies and how you can edit your preferences.
Refuse cookiesAccept cookies